NCT00411333View on ClinicalTrials.gov

Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Diabetic Retinopathy
Interventions
DRUG

triamcinolone acetonide (Kenalog)

Trial Locations (1)

44195

Cole Eye Institute, Cleveland

All Listed Sponsors
lead

National Eye Institute (NEI)

NIH

NCT00411333 - Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy | Biotech Hunter | Biotech Hunter